Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pomerantz Law Firm Files Class Action Against Achillion Pharmaceuticals Inc and Certain Officers


Friday, 8 Nov 2013 04:33pm EST 

Pomerantz Grossman Hufford Dahlstrom & Gross LLP announced that it has filed a class action lawsuit against Achillion Pharmaceuticals Inc (Achillion or the Company) and certain of its officers. The class action, filed in United States District Court, District of Connecticut, and docketed under 13-cv-1479, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Achillion between April 21, 2012 and September 27, 2013 both dates inclusive (the Class Period). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects, including the safety and suitability of its premier investigative drug for the treatment of hepatitis, sovaprevir. 

Company Quote

9.79
-0.08 -0.81%
20 Aug 2014